Press Releases

11.06.2018

• Shareholders agree to all draft proposals with large majority • Reverse stock split ratio of 5:1 • Generation of new capital

15.05.2018

• Next Level corporate strategy being implemented according to plan • Progress made in ongoing clinical trials and preparations underway for new studies in various indications • A licensing and development cooperation contract signed with...

27.04.2018

The biopharmaceutical company MOLOGEN AG has today published an initial data-based forecast for the expected date for the primary analysis of the pivotal IMPALA study.

25.04.2018

• First licensing agreement for lead compound lefitolimod concluded • Significant progress in studies • Company funding secured until the end of 2018 through successful capital measures

23.04.2018

The biopharmaceutical company MOLOGEN AG announced today the new dates for the publication of the Annual Financial Statements 2017 on 25 April 2018 and the holding of the Annual General Meeting on 8 June 2018.

20.04.2018

The biopharmaceutical company MOLOGEN AG announced today that the collaboration with ONCOLOGIE, agreed on in February 2018, is making good progress.

   

Displaying results 1 bis 7 von 15

Page 1

Page 2

Page 3

next

   

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.